[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Efferon JSC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":209},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,70,95,119,139,162,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636626","efferon-lps-hemoadsorption-in-in-patients-with-thermal-burns-100636626",false,"NCT07568132","Efferon LPS Hemoadsorption in in Patients With Thermal Burns","Extracorporeal Blood Purification Using Efferon LPS Hemoadsorption in Patients With Thermal Burns: Pilot Study","Inclusion Criteria:\n\n* Thermal burns (flame, scald, or contact burns), including cases combined with inhalation injury\n* Revised Frank Index (RFI) score ≥71 and ≤181\n* Indication for extracorporeal therapy within the first 10 days after injury\n* The patient's condition allows Efferon LPS therapy to be performed for at least 6 hours\n\nExclusion Criteria:\n\n* Isolated thermal-inhalation injury\n* Chemical, electrical, or solar burns of the skin\n* Combined skin burns with frostbite and\u002For general hypothermia\n* Combined trauma (electrical injury; traumatic brain injury other than concussion or mild cerebral contusion; skull, spinal, thoracic, pelvic, or femoral fractures) or acute pre-existing pathology prior to hospital admission (acute myocardial infarction, stroke, community-acquired pneumonia, or acute surgical conditions) that may influence the course and outcome of burn disease\n* Cardiopulmonary resuscitation at the pre-hospital stage\n* End-stage renal disease\n* Acute pulmonary embolism confirmed by imaging\n* Emergency surgical treatment\n* Any other condition which, in the investigator's opinion, precludes inclusion of the patient in the study","ALL","18 Years","65 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoadsorption using the Efferon® LPS device to reduce the severity of clinical symptoms and to prevent the progression of multiple organ dysfunction or to arrest its development in patients with burn disease with an RFI score ≥71 and ≤181.\n\nPatients will be randomized in two groups: control group receiving baseline therapy (including CRRT) and treatment group receiving baseline therapy and Efferon® LPS hemoadsorption in combination with CRRT.",[27],"Burns",[29,30,31,32],"Hemoadsorption","Hemoperfusion","Extracorporeal therapy","LPS adsorption","NOT_YET_RECRUITING","2026-04-28",{"date":36,"type":37},"2026-05-05","ACTUAL",{"date":39,"type":21},"2026-05-15",{"date":41,"type":21},"2028-02-27",{"name":43,"class":44},"Efferon JSC","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100633860","efferon-lps-hemoadsorption-in-cardiac-surgery-patients-100633860","NCT07532174","Efferon LPS Hemoadsorption in Cardiac Surgery Patients","Intraoperative and Early Postoperative Use of Lipopolysaccharide Adsorption (Efferon LPS) in Cardiac Surgery Patients to Reduce the Incidence of Multiple Organ Dysfunction Syndrome in the Postoperative Period","Inclusion Criteria:\n\n* Adult patients undergoing elective or emergency cardiac surgery with the use of cardiopulmonary bypass (CPB).\n* EuroSCORE II ≥6%\n\nExclusion Criteria:\n\n* Procalcitonin ≥2 ng\u002FmL\n* Severe chronic liver disease, defined as Child-Pugh class C (\\>10 points) or clinically manifest hepatic failure\n* Dialysis-dependent chronic kidney disease (CKD)\n* Ongoing immunosuppressive therapy, including corticosteroids or cytotoxic agents, excluding standard perioperative medications\n* Any other clinical condition that, in the investigator's opinion, would preclude the patient's participation in the study",{"count":54,"type":21},60,[24],"This randomized controlled study aims to evaluate the efficacy and safety of intraoperative and early postoperative hemoadsorption using the Efferon® LPS device in patients undergoing cardiac surgery with cardiopulmonary bypass in reducing the incidence and severity of multiple organ dysfunction syndrome (MODS) in the postoperative period. Each patient in the treatment group will undergo two hemoadsorption sessions: first during cardiopulmonary bypass (CPB) at the time of cardiac surgery, with the duration determined by the CPB time, and second within 24 hours postoperatively, for a minimum duration of 6 hours.",[58,59],"Cardiac Disease","Multiple Organ Dysfunction Syndrome",[29,30,31,32],"RECRUITING","2026-04-09",{"date":64,"type":37},"2026-04-15",{"date":64,"type":21},{"date":67,"type":21},"2028-01-31",{"name":43,"class":44},3,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":5},"100613482","efferon-lps-hemoadsorption-in-patients-with-acute-pancreatitis-100613482","NCT07267169","Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis","Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Acute Pancreatitis","Inclusion Criteria:\n\n* ≤ 5 days from the onset of acute pancreatitis\n* Acute pancreatitis of moderate or severe according to the Atlanta classification (2012)\n* Acute pancreatitis confirmed by tomography. Modified CTSI Pancreatitis Severity Index Score ≥ 4 points\n* APACHE II \\> 8\n* ≥ 2 points on the Sequential Organ Failure Assessment (SOFA) scale and\u002For ≥ 2 criteria of Systemic Inflammatory Response Syndrome (SIRS):\n* Body temperature ≥ 38 °C or ≤ 36 °C\n* Heart rate ≥ 90\u002Fmin\n* Respiratory rate ≥ 20\u002Fmin or hyperventilation with PaCO₂ ≤ 32 mmHg\n* Leukocytosis (≥ 12,000\u002Fμl) or leukopenia (≤ 4,000\u002Fμl) or left shift of leukocyte formula\n\nExclusion Criteria:\n\n* SOFA score \\> 12 points\n* Presence of an uncontrolled surgical infection focus\n* Development of septic complications - signs of infection\n* Acute pancreatitis as an exacerbation of chronic pancreatitis\n* Blood triglyceride level \\> 1000 mg\u002FdL (11.2 mmol\u002FL)\n* Liver cirrhosis (\\> 6 points by Child-Pugh classification)\n* Unresolved biliary hypertension syndrome\n* BMI ≥ 40\n* Dementia\n* Chronic kidney disease stage 4-5\n* Acute pulmonary embolism confirmed by CT\n* Acute myocardial infarction within the last 4 weeks\n* Acute cerebrovascular accident\n* Severe congestive heart failure\n* Uncontrolled bleeding (acute blood loss within the last 24 hours)","75 Years",{"count":79,"type":21},150,[24],"The goal of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoperfusion using the Efferon® LPS device in combination with hemofiltration (HF) \u002F hemodiafiltration (HDF), with the goal of reducing the severity of organ dysfunction (measured by SOFA score) in patients with acute pancreatitis.\n\nParticipants will be assigned to two groups for comparison: a control group receiving baseline therapy with HF\u002FHDF, and a treatment group receiving baseline therapy in combination with HF\u002FHDF and Efferon® LPS hemoadsorption.The therapy will be initiated within the first 24 hours after ICU admission and within 8 hours after patient enrollment.",[83],"Pancreatitis, Acute",[85,86],"acute pancreatitis","hemoperfusion","2026-04-06",{"date":89,"type":37},"2026-04-07",{"date":91,"type":37},"2026-03-30",{"date":93,"type":21},"2028-03-31",{"name":43,"class":44},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":45},"100622436","lipopolysaccharide-adsorption-efferon-lps-in-patients-with-ulcerative-colitis-and-crohn-disease-100622436","NCT07383597","Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease","A Randomized Pilot Study of LPS Adsorption Using the Efferon LPS Device in Patients With Ulcerative Colitis and Crohn's Disease During Disease Exacerbation","Inclusion Criteria:\n\n* Crohn's disease (ICD-10: K50), extensive disease, with a chronic continuous or relapsing course during an exacerbation (flare), including:\n\n  * Severe flare: CDAI ≥ 450 and\u002For SES-CD \\> 15;\n  * Moderate flare: CDAI 350-450 and\u002For SES-CD \\> 7, steroid-refractory.\n* Ulcerative colitis (ICD-10: K51), with a chronic continuous or relapsing course during an exacerbation (flare), including:\n\n  * Severe flare: Mayo score ≥ 10 and partial Mayo score ≥ 6;\n  * Moderate flare: Mayo score 6-9 and partial Mayo score ≥ 3, steroid-refractory or steroid-dependent.\n* Presence of signs and symptoms of ulcerative colitis or Crohn's disease for at least 3 months prior to study enrollment.\n* The diagnosis must be confirmed by clinical and endoscopic findings and supported by a histopathology report\n* The patient's condition allows Efferon LPS therapy to be performed for at least 2 hours\n\nExclusion Criteria:\n\n* Indeterminate colitis, radiation colitis, ischemic colitis,confirmed presence of megacolon, strictures, or stenosis causing symptoms of intestinal obstruction.\n* Expected need for bowel resection within 4 weeks after enrollment\n* Presence at hospitalization of a stoma, ileal pouch-anal anastomosis, or a fistula with purulent discharge (which, in the investigator's opinion, is likely to require surgical or medical intervention within 4 weeks after enrollment), or planned ileostomy or colostomy.\n* Partial or total colectomy, small bowel resection, or creation of a stoma (i.e., temporary or permanent colostomy, ileostomy, or other enterostomy) within 6 months prior to enrollment, or presence of an external or entero-enteric fistula with symptoms within 6 months prior to enrollment.\n* Suspected or diagnosed intra-abdominal or perianal abscess that has not been adequately treated.\n* Positive test for Clostridioides difficile toxin.\n* Positive test for infectious pathogens (including helminth eggs, parasites, or bacterial infections).\n* History of malignancy within the past 5 years, including solid tumors or hematologic malignancies (except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin in situ, or cervical dysplasia\u002Fcancer that has been surgically excised with complete resolution), or colonic mucosal dysplasia that has not been completely removed.\n* End-stage renal disease.\n* Acute pulmonary embolism confirmed by imaging.\n* Acute myocardial infarction within the last 4 weeks.\n* Acute cerebrovascular accident (stroke) within the last 8 weeks.\n* Dementia.\n* Uncontrolled bleeding (acute blood loss within the last 24 hours).\n* History or current evidence of recurrent or chronic viral infection (e.g., hepatitis B virus, hepatitis C virus, or human immunodeficiency virus \\[HIV\\]).\n* Alcohol or drug dependence.\n* Any other condition that, in the investigator's opinion, would preclude the patient's participation in this study.",{"count":103,"type":21},40,[24],"The goal of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoperfusion using the Efferon® LPS device in patients with ulcerative colitis and Crohn disease.\n\nParticipants will be assigned to two groups for comparison: a control group receiving baseline therapy and a treatment group receiving baseline therapy in combination with Efferon® LPS hemoadsorption.",[107,108,109],"Crohn Disease","Ulcerative Colitis","Inflammatory Bowel Diseases",[29,30,31,32],"2026-02-09",{"date":113,"type":37},"2026-02-11",{"date":115,"type":21},"2026-03-01",{"date":117,"type":21},"2028-03-01",{"name":43,"class":44},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":126,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":138,"locationsCount":45},"100612906","lipopolysaccharide-adsorption-efferon-lps-in-patients-with-thermal-burns-100612906","NCT07259668","Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Thermal Burns","An Observational Pilot Study Evaluating the Efficacy and Safety of LPS Adsorption Using the Efferon LPS Device in Patients With Thermal Burns","Inclusion Criteria:\n\n* Thermal burn of Ⅱ and Ⅲ severity with a lesion area of 40% or more (ICD-10: T20-T25, T29)\n* Burn disease in the stage of acute toxemia or septicemia\n* Frank Index ≥ 90 (Frank Index quantifies burn severity based on the depth and total surface area of the skin lesion)\n* The patient's condition allows for Efferon LPS therapy for at least 6 hours\n\nExclusion Criteria:\n\n* Isolated thermal inhalation injury\n* Charlson Comorbidity Index \\> 8\n* Dementia\n* End-stage renal failure\n* Acute pulmonary embolism confirmed by CT\n* Acute myocardial infarction within the past 4 weeks\n* Acute cerebrovascular accident\n* Uncontrolled bleeding (acute blood loss within the past 24 hours)\n* Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion in the study",{"count":127,"type":21},15,"OBSERVATIONAL","This observational pilot study aims to establish criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS device in adult patients with burn injury. Participants will be prospectively enrolled into the treatment group and compared with a retrospectively selected control group. Each patient in the treatment group will undergo two hemoadsorption sessions, each lasting 6-12 hours, with a 24 hours interval between sessions. The procedures may be performed in combination with hemofiltration or hemodiafiltration at the investigator's discretion.",[27],[29,30,31,32],"2026-01-21",{"date":134,"type":37},"2026-01-22",{"date":136,"type":37},"2025-12-08",{"date":93,"type":21},{"name":43,"class":44},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},"100612080","lipopolysaccharide-adsorption-efferon-lps-neo-in-children-with-thermal-burns-100612080","NCT07248930","Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Thermal Burns","An Observational Pilot Study Evaluating the Efficacy and Safety of LPS Adsorption Using the Efferon LPS NEO Device in Children With Thermal Burns","Inclusion Criteria:\n\n* Thermal burn of Ⅱ and Ⅲ severity with a lesion area of 40% or more (ICD-10: T20-T25, T29)\n* Frank index \\>90 (Frank Index quantifies burn severity based on the depth and total surface area of the skin lesion)\n* Start of hemoadsorption no later than 5 days after admission to the ICU\n* The patient should receive adequate infusion therapy (at least 30 mL\u002Fkg) from the moment of inclusion in the study until the first sorption\n* The patient's condition allows Efferon LPS NEO therapy to be performed for at least 6 hours\n\nExclusion Criteria:\n\n* Presence of end-stage renal disease\n* Acute pulmonary embolism, confirmed by CT scan\n* Uncontrolled bleeding (acute blood loss within the last 24 hours)","1 Year","14 Years",{"count":149,"type":21},30,"This observational pilot study aims to identify criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS NEO device in pediatric burn injury. Participants will be prospectively assigned to the treatment group and compared with a retrospectively selected control group. Each patient in the treatment group will undergo two hemoadsorption sessions, each lasting 6-12 hours, with an interval of 24-120 hours between procedures. The sessions may be performed in combination with hemofiltration or hemodiafiltration at the discretion of the investigator.",[27],[29,30,31,32],"2025-11-18",{"date":155,"type":37},"2025-11-25",{"date":157,"type":37},"2025-10-01",{"date":159,"type":21},"2027-03-31",{"name":43,"class":44},2,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":45},"100589555","efferon-ct-hemoadsorption-for-cardiogenic-shock-in-acute-myocardial-infarction-100589555","NCT06955936","Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction","An Open Randomized Study on the Efficacy and Safety of Hemoadsorption With Efferon CT in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction","Inclusion Criteria:\n\n* Not more than 4 hours after diagnosis Cardiogenic shock complicating acute myocardial infarction\n* Stages B - C of cardiogenic shock according to SCAI\n* Patient condition allows treatment with Efferon® CT device for at least 4 hours\n* SOFA score 12 or less\n\nExclusion Criteria:\n\n* Broken-heart syndrome (takotsubo cardiomyopathy)\n* Postcardiotomy cardiogenic shock\n* Acute myocardial infarction within the last 4 weeks\n* Myocarditis\n* Cardiac trauma\n* Charlson comorbidity index greater than 9 points\n* Chronic kidney disease, stage 5 D (requiring continuous hemodialysis)\n* Acute pulmonary embolism\n* Acute cerebral circulatory collapse\n* Transfusion reaction\n* Patients on immunosuppressive therapy for cancer and autoimmune diseases\n* Pregnancy\n* Any other clinical condition of the patient that in the opinion of the investigator precludes inclusion in this study","80 Years",{"count":54,"type":21},[24],"Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction.\n\nCardiogenic shock is a well-known and potent trigger of the immune response, ischemia\u002Freperfusion organ damage, hemolysis and release of free hemoglobin. The activation of immune cells leads to the release of cytokines and inflammatory mediators such as IL-6, IL-8, activated complement and others. As a result of myocardial ischaemia and reperfusion injury, a multiorgan dysfunction syndrome may develop.\n\nThe Efferon CT hemoadsorption device effectively removes cytokines and other pro-inflammatory molecules (≤55 kDa). This study evaluates whether this blood-filtering therapy can prevent organ failure in acute myocardial infarction patients with cardiogenic shock by eliminating inflammation-inducing mediators.",[174,175],"Myocardial Infarction","Cardiogenic Shock",[29,31,177,30],"Cytokine adsorption","2025-06-02",{"date":180,"type":37},"2025-06-05",{"date":182,"type":37},"2025-04-29",{"date":184,"type":21},"2027-07-31",{"name":43,"class":44},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":45},"100492656","combination-of-cytokine-hemosorption-and-high-volume-hemofiltration-in-acute-pancreatitis-100492656","NCT05694988","Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis","An Open Controlled Randomized Study of the Efficacy and Safety of the Method of Combined Use of Non-selective Hemosorption (Efferon CT) and High Volume Hemofiltration (HVHF) in Patients With Acute Pancreatitis.","Inclusion Criteria:\n\n* Age from 18 to 75 years old,\n* Acute pancreatitis according to the Atlanta classification of OP (2012), without signs of infection,\n* Acute pancreatitis confirmed by tomography. Score according to the Modified CTSI Pancreatitis Severity Index: from 4 points and above,\n* No more than 3 days from the onset of an attack of acute pancreatitis,\n* APACHE II score - at least 10,\n* The patient must receive adequate fluid therapy (at least 30 ml\u002Fkg) from the time of randomization until the first therapy,\n* The patient's condition allows therapy for at least 4 hours.\n\nExclusion Criteria:\n\n* Age over 75,\n* More than 3 days from the onset of an attack of acute pancreatitis,\n* An attack of acute pancreatitis, as an exacerbation of chronic pancreatitis.\n* Acute pancreatitis as a complication of a surgical operation,\n* DS - Septic shock (Sepsis-3, 2016)\n* The presence of a focus of non-sanitized surgical infection,\n* Charlson comorbidity index\\> 5 points,\n* Critical hypoxemia (PaO2\u002FFiO2 \\\u003C 150 mm Hg),\n* GCS level of consciousness \\\u003C 12 points,\n* Obesity 3 degrees and above (weight over 150 kg),\n* Blood triglyceride level \\>1000 mg\u002Fdl, (11.2 mmol\u002Fl),\n* Dementia,\n* Inability to achieve or maintain min SBP ≥ 65 mm Hg. Art., despite vasopressor therapy and infusion therapy in tech. 24 hours\n* Presence of end-stage renal disease requiring RRT,\n* The presence of cirrhosis of the liver (\\> 5 points according to the Child-Pugh classification),\n* Unresolved biliary hypertension syndrome,\n* Acute thromboembolism of the pulmonary artery, confirmed by tomography,\n* Acute myocardial infarction within the last 4 weeks,\n* Acute cerebrovascular accident,\n* Transfusion reaction,\n* Severe congestive heart failure,\n* Uncontrolled bleeding (acute blood loss in the last 24 hours).",{"count":54,"type":21},[24],"Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF). Due to the lack of etiological therapy, the treatment of acute pancreatitis is predominantly symptomatic.\n\nSeverity and mortality are associated with early systemic inflammatory response syndrome (SIRS) and septic complications in the later stages of the disease.\n\nIn connection with a pronounced inflammatory reaction (\"cytokine storm\") in the early phase of endogenous intoxication of acute pancreatitis, a promising therapeutic approach is the extracorporeal removal of cytokines.\n\nThis prospective study intends to study the effect of hemoperfusion (Efferon CT) in combination with high-volume hemofiltration (HVHF) on the severity of symptoms of endogenous intoxication and indicators of organ dysfunction in acute pancreatitis.",[197],"Acute Pancreatitis Without Necrosis or Infection",[85,199,200,86],"sepsis","cytokines apsorbtion","2025-02-25",{"date":203,"type":37},"2025-02-27",{"date":205,"type":37},"2022-11-01",{"date":207,"type":21},"2026-04-30",{"name":43,"class":44},""]